课题基金 / 基金详情

Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
批准号:
10589801
负责人:
OFER LEVY
金额:
$11.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-10 至 2027-02-28

项目摘要

项目成果

OFER LEVY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY: IDEAL Administrative Core Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3) research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute streamlined processes which facilitate productive interactions among investigators from each IDEAL Project and Core. We will achieve this goal by pursuing the following Specific Aims (SAs): SA1. Provide infrastructure for administrative leadership aimed at building an interactive and collaborative working team resulting in maximal project synergy. SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as seminars/symposia focused on the IDEAL project. SA3. Manage and optimize communication within our IDEAL team and between our team, the other NIH supported IDEAL teams and the IDEAL Steering Committee. SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by implementing recommendations of the Conflicts Resolution Group (CRG). SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress reports sent to the NIH. SA6. Protect intellectual property rights of our investigators and execute material transfer agreements. SA7. Implement the data management/sharing plan among investigators within and outside of our IDEAL team. Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10435035
  • 项目类别:
  • 资助金额:
    $166.59万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10589826
  • 项目类别:
  • 资助金额:
    $22.79万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10435043
  • 项目类别:
  • 资助金额:
    $19.86万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10589800
  • 项目类别:
  • 资助金额:
    $154.65万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
海外基金